/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 ("CB1") a key GPCR involved in metabolic regulation.
$1.77
+$0.20 (+12.42%)
EOD Sep 18, 2026
ROIC dropped from -69.29% to -103.37%, capital efficiency is deteriorating. Negative free cash flow of -$43M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$50M
▼ -110.5% YoY
Op. Margin
—
ROIC
-262.12%
▼ -34.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$39M
▼ -60.5% YoY
Op. Cash Flow (TTM)
-$39M
▼ -70.6% YoY
Net Debt
-$10M
Net Cash Position
Cash & Equiv.
$10M
Continue Research
SourceComputed from the 10-Q filed 14 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 15 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.